- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.09. | Petros Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 25.06. | Petros Pharmaceuticals will Tochtergesellschaft ausgliedern, um Finanzen zu verbessern | 12 | Investing.com Deutsch | ||
| 25.06. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position | 469 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / June 25, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the... ► Artikel lesen | |
| 20.06. | Petros Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.05. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets | 409 | ACCESS Newswire | The Company Intends to Appeal the Delisting Determination NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on... ► Artikel lesen | |
| 21.05. | Petros Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| PETROS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 20.05. | Petros Pharmaceuticals partners with Innolitics for SaaS platform | 7 | Investing.com | ||
| 20.05. | Petros Pharmaceuticals partners with Innolitics to accelerate SaaS platform development | 3 | Seeking Alpha | ||
| 20.05. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device Developer | 584 | ACCESS Newswire | With more than $10m in cash, and a significantly reduced burn rate, the Company is positioned to fully fund the development of its technology platform. NEW YORK, NY / ACCESS Newswire / May 20, 2025... ► Artikel lesen | |
| 15.05. | Petros Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
| 06.05. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform | 366 | ACCESS Newswire | Company continues to innovate and develop its SaaS-based platform to facilitate Rx-to-OTC switch in line with recent President Trump Executive Order NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Petros... ► Artikel lesen | |
| 01.05. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches | 416 | ACCESS Newswire | Licensable platform intended to facilitate industry compliance with President Trump's recent Executive Order to expand access to medicines through OTC approvals under his Make America Healthy Again... ► Artikel lesen | |
| 29.04. | Petros Pharmaceuticals, Inc.: Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms | 473 | ACCESS Newswire | Company's AI and Big Data technology positioned to drive strong industry collaborationCompany also announces certain corporate actions NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Petros Pharmaceuticals... ► Artikel lesen | |
| 20.03. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications | 528 | ACCESS Newswire | Company to integrate industry leading big data technology solutions into its AI-driven platform to expand capabilities in identifying eligible patients to receive formerly Rx medications over the counter... ► Artikel lesen | |
| 25.02. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study | 626 | ACCESS Newswire | Proprietary technology utilizing AI and big data integrations to enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Petros Pharmaceuticals... ► Artikel lesen | |
| 18.02. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants | 519 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter... ► Artikel lesen | |
| 07.01. | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules | 537 | ACCESS Newswire | Proprietary technology developing quantum computing and applying AI to better enable Rx to OTC switch candidates across multiple indicationsNEW YORK, NY / ACCESSWIRE / January 7, 2025 / Petros Pharmaceuticals... ► Artikel lesen | |
| 19.12.24 | Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Featured in "New Era of Healthcare, AI, Data and Consumer Empowerment" | 508 | ACCESS Newswire | Company positions itself for new innovation utilizing AI and quantum computing to help expand patient access to drugs via OTC access NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Petros Pharmaceuticals... ► Artikel lesen | |
| 17.12.24 | Petros Pharmaceuticals, Inc.: Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually | 417 | ACCESS Newswire | Working to identify quantum computing partnerships to strengthen our AI technology to include critical health records to better enable Rx to OTC switch candidates across multiple indicationsNEW YORK... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 26,500 | -1,67 % | Aktien Frankfurt Ausblick: Kursgewinne - Entspannung zwischen USA und China | FRANKFURT (dpa-AFX) - Nach Anzeichen einer Entspannung im US-chinesischen Handelsstreit zeichnet sich am Montag am deutschen Aktienmarkt ein positiver Wochenauftakt ab. Der X-Dax signalisierte den... ► Artikel lesen | |
| GILEAD SCIENCES | 104,68 | +0,89 % | Chance für Anleger?: Gilead gibt Zahlen bekannt - Boost für Gewinnprognose? | Gilead gab steigende Umsätze mit HIV-Medikamentenverkäufen bekannt. Das Unternehmen erwartet in Zukunft Großes.Das Unternehmen meldete am Donnerstag einen Anstieg der HIV-Medikamentenverkäufe um 4 Prozent... ► Artikel lesen | |
| AURORA CANNABIS | 4,205 | -2,21 % | Aurora Cannabis Inc.: Aurora Announces Investment into German Manufacturing Facility | NASDAQ| TSX: ACB
Facility investment includes adopting the company's unmatched global manufacturing practices for superior cannabis production and quality
EDMONTON... ► Artikel lesen | |
| ABBVIE | 185,40 | -1,70 % | AbbVie Reports Third-Quarter 2025 Financial Results | Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent; Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent; These Results... ► Artikel lesen | |
| CANOPY GROWTH | 1,052 | -2,95 % | Cannabis-Aktien mit Trump-Schub: Bioxyne, Aurora und Canopy Growth im Fokus | ||
| ELI LILLY | 766,30 | +3,16 % | Live-Event: Blickwechsel Stoffwechsel von Lilly in Kooperation mit der Universitätsmedizin Mainz / Neue Impulse für die Adipositasversorgung von morgen: Interdisziplinäre Lösungen, starker Dialog | Bad Homburg (ots) - Die Veranstaltungsreihe "Blickwechsel Stoffwechsel" hat mit der "Zukunftswerkstatt Adipositas" in Mainz eine starke neue Wegmarke für die Adipositasversorgung gesetzt. Initiiert... ► Artikel lesen | |
| ASTRAZENECA | 141,05 | -0,63 % | JEFFERIES stuft ASTRAZENECA auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Astrazeneca von 10900 auf 15000 Pence angehoben und die Aktien von "Hold" auf "Buy" hochgestuft. Analyst Michael Leuchten... ► Artikel lesen | |
| HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
| TILRAY BRANDS | 1,128 | -3,84 % | Mehr als "nur" Cannabis-Blüten - Bioxyne setzt auf Produktvielfalt im Wettbewerb mit Tilray, High Tide und Aurora | ||
| BRISTOL-MYERS SQUIBB | 39,900 | -0,03 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| TEVA | 17,800 | +0,28 % | Teva Pharmaceutical Industries Ltd: Teva Kicks Off 'The Other TD' to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis | This football season, Teva is increasing education around tardive dyskinesia (TD) by launching 'The Other TD' campaignTD is a chronic movement disorder impacting one in four people who take certain... ► Artikel lesen | |
| ABBOTT LABORATORIES | 107,10 | -0,17 % | ABBOTT LABORATORIES - 10-Q, Quarterly Report | ||
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | CSE Bulletin: Suspensions - Blender Bites Limited, TAAT Global Alternatives Inc. | Toronto, Ontario--(Newsfile Corp. - Le 16 mai/May 2025) - Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as... ► Artikel lesen | |
| DERMAPHARM | 34,150 | 0,00 % | EQS-DD: Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
03.11.2025 / 11:44... ► Artikel lesen | |
| BIOTEST | 30,000 | 0,00 % | EQS-News: Biotest AG: Absage der außerordentlichen Hauptversammlung am 28. Oktober 2025 | EQS-News: Biotest AG
/ Schlagwort(e): Hauptversammlung
Biotest AG: Absage der außerordentlichen Hauptversammlung am 28. Oktober 2025
23.10.2025 / 13:16 CET/CEST
Für... ► Artikel lesen |
PETROS PHARMACEUTICALS INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,066 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PETROS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.